Karyopharm Therapeutics Inc.

09/11/2025 | Press release | Distributed by Public on 09/11/2025 14:33

Management Change/Compensation (Form 8-K)

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 5, 2025, Mansoor Raza Mirza, M.D., a member of the Board of Directors (the "Board") of Karyopharm Therapeutics Inc. (the "Company"), notified the Company of his resignation from the Board, effective as of September 8, 2025. Dr. Mirza's resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Dr. Mirza is also resigning from his position as Chief Oncologist at Copenhagen University National Medical Center, effective October 1, 2025, to focus his professional efforts on his new executive role in industry. In connection with Dr. Mirza's resignation, the consulting agreement between the Company and Mirza Consulting, an entity wholly-owned by Dr. Mirza, for consulting and advisory services provided to the Company by Dr. Mirza was terminated effective as of September 8, 2025.

Karyopharm Therapeutics Inc. published this content on September 11, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on September 11, 2025 at 20:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]